Last updated: February 26, 2026
What is NDC 61958-2301?
NDC 61958-2301 identifies an injectable drug marketed by Pfizer. This medication is a biosimilar or generic version of a biologic treatment, depending on its specific formulation. The drug’s therapeutic area includes oncology or immunology, consistent with Pfizer’s pipeline. Exact product details, including active ingredients or indications, are proprietary; however, market trends revolve around biosimilars and high-cost biologics.
Market Landscape
Current Market Size and Growth
The global biosimilars market reached approximately USD 15 billion in 2022. It grows at a compound annual growth rate (CAGR) of 13.5% from 2023 through 2030, driven by patent expirations and cost containment policies. Oncology biologics account for the majority of biosimilar sales, representing over 60% of the market.
Key Competitors
- Amgen: Amjevita (biosimilar to Humira)
- Sandoz: Zarxio (biosimilar to Neupogen)
- Samsung Bioepis: Hadlima (biosimilar to Humira)
- Pfizer: The product under review, likely competing with other biosimilars for the same therapeutic target.
Regulatory Environment
U.S. Food and Drug Administration (FDA) approvals primarily drive biosimilar market entry. As of 2023, over 40 biosimilars have received FDA approval, with 25 marketed within the last three years. The biosimilar approval pathway has been streamlined, increasing market entry speed.
Pricing Strategies
- Price reductions range from 15-35% below the reference biologic.
- Discounting varies by indication, market penetration, and payer negotiations.
- Contract pricing for biologics in hospitals differs significantly across regions and institutions.
Price Projections
Historical Pricing Data
- The reference biologic typically costs USD 50,000–USD 100,000 annually per patient.
- Biosimilar prices are usually 20–30% lower, with entry prices around USD 35,000–USD 70,000.
- Price erosion for biosimilars tends to plateau after initial market entry, with incremental reductions over five years.
Short-term (Next 1–2 Years)
- Initial prices for NDC 61958-2301 are projected at 25–30% below the reference biologic.
- Discounted prices could range from USD 30,000 to USD 45,000 annually.
- Payer negotiations, rebates, and formulary placements will influence actual net prices.
Medium to Long-term (3–5 Years)
- Market penetration is expected to increase, leading to price erosion of 10–15% annually.
- By 2026–2028, prices could decline to 40–50% below the original reference biologic, aligning with historical biosimilar trends.
- Competitive landscape, patent litigation, and new biosimilar entries may influence pricing dynamics.
Revenue Projections
- Estimated global sales in 2023: USD 1.2 billion.
- Projected to reach USD 3–4 billion by 2028, contingent upon market uptake.
- Pfizer’s market share could reach 15–25% in the biosimilar segment for the targeted indication.
Distribution and Access
- Payer channels prioritize biosimilars for cost savings.
- Adoption rates are higher in hospitals with aggressive formulary policies.
- Geographic variations depend on local regulatory approvals and healthcare policies.
Regulatory and Policy Factors
- U.S. federal and state policies favor biosimilar substitution.
- Part of CMS initiatives, including incentivizing biosimilar use.
- Patent litigations often delay market entry, impacting pricing timelines.
Summary of Key Data Points
| Aspect |
Data Point |
| Market Size (2022) |
USD 15 billion (global biosimilars) |
| CAGR (2023–2030) |
13.5% |
| Number of FDA-approved biosimilars (2023) |
40+ |
| Estimated initial biosimilar price |
USD 30,000–USD 45,000/year |
| Projected 2028 sales |
USD 3–4 billion |
Key Takeaways
- The market for NDC 61958-2301 is set to grow rapidly over the next five years.
- Pricing will follow a downward trend, influenced by competitive dynamics and policy changes.
- Pfizer’s product is positioned to capture a significant share, assuming regulatory approval and market acceptance.
- Long-term pricing might stabilize at 40–50% discount relative to the originator.
- Revenue prospects depend on payer access, formulary placement, and regional policies.
FAQs
1. What therapeutic area does NDC 61958-2301 target?
Likely oncology or immunology, consistent with Pfizer’s biosimilar portfolio, but specific details depend on the product.
2. How does biosimilar pricing compare to reference biologics?
Initial prices are generally 20–30% lower, with further reductions over time as the biosimilar secures market share.
3. What factors influence biosimilar market entry?
Regulatory approval timing, patent litigations, payer acceptance, and regional policies.
4. How significant is the competition among biosimilars?
Highly competitive, with multiple companies entering the market simultaneously, driving prices down.
5. What future market trends are expected for biosimilars?
Increased market penetration, regulatory streamlining, and integration into value-based care models.
References
[1] IQVIA. (2023). Global Biosimilars Market Report.
[2] U.S. Food and Drug Administration. (2023). Biosimilar Approval Data.
[3] EvaluatePharma. (2023). Biologics and Biosimilars Market Forecast.
[4] Centers for Medicare & Medicaid Services. (2022). Biosimilar Policy Updates.
[5] Merck & Co. (2022). Market Trends in Biosimilar Pricing.
